Eli Lilly's Strategic Acquisition of Merida Biosciences: What Investors Need to Know
Eli Lilly's $2.875 billion acquisition of Merida Biosciences signals a strong M&A appetite in the pharmaceutical sector.
Eli Lilly's Strategic Move: Acquiring Merida Biosciences for Up to $2.875 Billion
Eli Lilly's acquisition of Merida Biosciences signals a shift in strategy and potential growth avenues.
Tech Earnings Showcase Strength in AI: Salesforce, CrowdStrike, and Nvidia
Salesforce, CrowdStrike, and Nvidia's earnings highlight a bullish outlook for tech stocks amid strategic AI spending.
Moderna's Stock Soars: Analyzing the Impact of mRNA Milestone on Investors
Moderna shares surged on news of a significant milestone in its cancer vaccine trial, suggesting a bright future for the biotech.
Walmart's Earnings Miss: A Bellwether for Consumer Spending?
Walmart's disappointing earnings could signal trouble for U.S. consumer spending, raising questions about retail health.
Jazz Pharmaceuticals' $1.32B Acquisition: A Game-Changer for Investors?
Jazz Pharmaceuticals is acquiring Actio Biosciences for $1.32B, raising questions about the biotech sector's future and investor sentiment.
Tarsus Pharmaceuticals Expands Eye Care Portfolio with Alkeus Acquisition
Tarsus Pharmaceuticals solidifies its eye care leadership with the acquisition of Alkeus Pharmaceuticals, targeting a major unmet need.
Pfizer's Q2 Performance: A Shift Towards Non-Covid Growth
Pfizer exceeds Q2 earnings expectations, signaling a shift to non-Covid revenue streams and raising guidance for the healthcare sector.
Palantir's Earnings Surge: What It Means for AI Investments
Palantir's strong Q2 earnings and rising shares suggest a shift in AI adoption dynamics.
Vertiv's Disappointing Quarter: What Investors Need to Know After 17% Stock Plunge
Vertiv's stock dropped 17% following a disappointing quarter, but CEO insists the issues are temporary. What does this mean for investors?
Humana's Q2 Earnings Beat: What It Means for Investors Amid High Expectations
Humana's Q2 earnings surpass estimates, but the maintained profit outlook raises questions amid rising medical costs.
Coca-Cola's Q2 Earnings: Key Insights for Investors as KO Stock Surges
Coca-Cola's upcoming Q2 earnings report is crucial for investors, especially given its 19% stock surge this year.